Numab AG
Numab is a Swiss biotech company that innovates and develops antibody-based therapeutics. A particular focus is given to the discovery of protein therapeutics against non-traditional antibody targets, such as complex membrane proteins. Numab’s proprietary discovery technology is particularly well suited to approach this class of drug-targets that formerly was inaccessible to most protein-binder platforms.
Contact
![]()
![]()
Einsiedlerstrasse 34
CH-8820 Wädenswil
Switzerland
Tel. +41 (0)44 533 04 71
info@numab.com
www.numab.com

Dr. David Urech (co-CEO, CSO)

Dr. Oliver Middendorp (co-CEO, CBO)